Physician profile
Anthony U Ekwenchi
NPI 1376765180
$5,262.09
in general payments reported to CMS, 2019-2025
28 companies · $1,442 in 2025
The $1,442 reported for 2025 was more than what 99% of Hospice and Palliative Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $727).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $242 · 2021: $659 · 2022: $955 · 2023: $1,194 · 2024: $612 · 2025: $1,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,244 · Education: $4.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,244.00 |
| Education | $4.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,051.61 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $704.33 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $583.16 | 2019-2025 | Uzedy, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $387.25 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $341.95 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $339.84 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $338.44 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $296.67 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Vanda Pharmaceuticals INC. | $257.49 | 2022-2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $235.19 | 2020-2022 | |
| Eisai INC. | $75.56 | 2020 | |
| Avion Pharmaceuticals | $75.35 | 2023 | Methylphenidate Hydrochloride, Dhivy |
| Lundbeck LLC | $72.16 | 2022-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $68.97 | 2022-2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $66.38 | 2020-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $64.17 | 2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $47.52 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $45.97 | 2021-2024 | |
| Noven Therapeutics, LLC | $33.78 | 2020-2021 | |
| Allergan, INC. | $32.24 | 2019-2020 | |
| Luye Pharma (USA) Ltd. | $24.49 | 2025 | Erzofri Extended-Release |
| Masimo Corporation | $21.07 | 2023 | Emma and Isa |
| Avanir Pharmaceuticals, INC. | $19.82 | 2022 | |
| Tris Pharma INC | $18.37 | 2024 | Dyanavel Xr |
| Indivior INC. | $16.84 | 2023 | Perseris |
| Neuronetics, INC. | $15.81 | 2019 | |
| Neos Therapeutics, Lp | $15.31 | 2025 | Exxua |
| Almatica Pharma LLC | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Ekwenchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.